title: Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.
abstract: OBJECTIVE
  To conduct a controlled trial of bevacizumab for the treatment of symptomatic radiation necrosis of the brain.
  
  
  METHODS
  A total of 14 patients were entered into a placebo-controlled randomized double-blind study of bevacizumab for the treatment of central nervous system radiation necrosis. All patients were required to have radiographic or biopsy proof of central nervous system radiation necrosis and progressive neurologic symptoms or signs. Eligible patients had undergone irradiation for head-and-neck carcinoma, meningioma, or low- to mid-grade glioma. Patients were randomized to receive intravenous saline or bevacizumab at 3-week intervals. The magnetic resonance imaging findings 3 weeks after the second treatment and clinical signs and symptoms defined the response or progression.
  
  
  RESULTS
  The volumes of necrosis estimated on T(2)-weighted fluid-attenuated inversion recovery and T(1)-weighted gadolinium-enhanced magnetic resonance imaging scans demonstrated that although no patient receiving placebo responded (0 of 7), all bevacizumab-treated patients did so (5 of 5 randomized and 7 of 7 crossover) with decreases in T(2)-weighted fluid-attenuated inversion recovery and T(1)-weighted gadolinium-enhanced volumes and a decrease in endothelial transfer constant. All bevacizumab-treated patients-and none of the placebo-treated patients-showed improvement in neurologic symptoms or signs. At a median of 10 months after the last dose of bevacizumab in patients receiving all four study doses, only 2 patients had experienced a recurrence of magnetic resonance imaging changes consistent with progressive radiation necrosis; one patient received a single additional dose of bevacizumab and the other patient received two doses.
  
  
  CONCLUSIONS
  The Class I evidence of bevacizumab efficacy from the present study in the treatment of central nervous system radiation necrosis justifies consideration of this treatment option for people with radiation necrosis secondary to the treatment of head-and-neck cancer and brain cancer.
authors.affiliation: Department of Neuro-Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77230-1402, USA. vlevin49@comcast.net
authors.forename: Victor A
authors.initials: VA
authors.lastname: Levin
authors.forename: Luc
authors.initials: L
authors.lastname: Bidaut
authors.forename: Ping
authors.initials: P
authors.lastname: Hou
authors.forename: Ashok J
authors.initials: AJ
authors.lastname: Kumar
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Wefel
authors.forename: B Nebiyou
authors.initials: BN
authors.lastname: Bekele
authors.forename: Jai
authors.initials: J
authors.lastname: Grewal
authors.forename: Sujit
authors.initials: S
authors.lastname: Prabhu
authors.forename: Monica
authors.initials: M
authors.lastname: Loghin
authors.forename: Mark R
authors.initials: MR
authors.lastname: Gilbert
authors.forename: Edward F
authors.initials: EF
authors.lastname: Jackson
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001921:Brain / Q000473:pathology* / Q000528:radiation effects; D001932:Brain Neoplasms / Q000532:radiotherapy; D002490:Central Nervous System / Q000528:radiation effects; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D005910:Glioma / Q000532:radiotherapy; D006258:Head and Neck Neoplasms / Q000532:radiotherapy; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008577:Meningeal Neoplasms / Q000532:radiotherapy; D008579:Meningioma / Q000532:radiotherapy; D008875:Middle Aged; D009336:Necrosis / Q000188:drug therapy / Q000209:etiology; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010919:Placebos; D011832:Radiation Injuries / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018696:Neuroprotective Agents; D010919:Placebos; D000068258:Bevacizumab
references.citation: Neurology. 1994 Nov;44(11):2020-7
references.pmid: 7969953
references.citation: Lancet. 1995 Oct 28;346(8983):1171
references.pmid: 7475646
references.citation: Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):323-6
references.pmid: 17236958
references.citation: Radiology. 2000 Nov;217(2):377-84
references.pmid: 11058631
references.citation: Cancer Res. 1997 Oct 15;57(20):4593-9
references.pmid: 9377574
references.citation: Cancer Res. 1986 Nov;46(11):5629-32
references.pmid: 3756910
references.citation: J Korean Med Sci. 2004 Dec;19(6):879-86
references.pmid: 15608402
references.citation: J Neurooncol. 2009 Aug;94(1):63-8
references.pmid: 19189055
references.citation: Cancer Metastasis Rev. 1993 Sep;12(3-4):303-24
references.pmid: 8281615
references.citation: J Exp Med. 1991 Nov 1;174(5):1275-8
references.pmid: 1940805
references.citation: Neurologist. 2003 Jul;9(4):180-8
references.pmid: 12864928
references.citation: Cancer. 2003 Apr 15;97(8):2019-26
references.pmid: 12673733
references.citation: J Neuropathol Exp Neurol. 1999 Oct;58(10):1051-60
references.pmid: 10515228
references.citation: Science. 1983 Feb 25;219(4587):983-5
references.pmid: 6823562
references.citation: Cancer Res. 2001 Apr 15;61(8):3348-54
references.pmid: 11309291
references.citation: J Magn Reson Imaging. 1997 Jan-Feb;7(1):91-101
references.pmid: 9039598
references.citation: J Clin Oncol. 1994 Mar;12(3):627-42
references.pmid: 8120563
references.citation: Acad Radiol. 2006 Oct;13(10):1254-65
references.pmid: 16979075
references.citation: Cancer Detect Prev. 1998;22(1):20-9
references.pmid: 9466045